ReproNovo was founded in 2021 by an experienced executive team with a strong track record in fertility and women’s health. With decades of immersion in reproductive medicine, the ReproNovo team brings strong expertise in drug development, regulatory affairs and business development, alongside a deep understanding of patient needs and the treatment landscape.
Our team has successfully brought numerous therapies to market. Drawing upon our in-depth experience in designing and executing clinical programs, we are strongly committed to delivering innovative therapeutic solutions for male and female fertility and pioneering treatment options for conditions like adenomyosis.
In pursuit of this objective, we have built a company aimed at addressing critical gaps in fertility and women’s health worldwide, targeting areas with significant unmet medical need, limited or no approved treatment options and with no real competition.
Headquartered in Lausanne, Switzerland, ReproNovo has its primary development team in Copenhagen, Denmark and an additional development site in Barcelona, Spain, with team members also based in the U.S.
Meet our team
Our experienced team is composed of a select group of highly respected experts in their fields with diverse backgrounds in science, development, regulatory affairs, deal-making and more. Together we are dedicated to advancing new scientific approaches to fertility and women’s health.
We are backed by renowned international investors who bring deep knowledge of fertility and women’s health and share our commitment to addressing critical gaps in the treatment landscape.
”
As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients. We were highly impressed by the ReproNovo team, whose members have a strong track record in this field, having brought a number of compounds successfully through clinical development and onto the market. Their deep understanding of the field will enable them to effectively address critical unmet needs that have a strong impact on society.
We are proud to support a company working to address critical gaps in reproductive medicine and women’s health. This includes indications such as adenomyosis where no treatments currently exist and other areas, including male infertility where limited options are available and female infertility where the aim is to improves success rates. We look forward to being a part of ReproNovo’s journey for the long term as they strive to improve the global treatment landscape and bring novel solutions to patients urgently in need of effective therapies.
ReproNovo’s innovative approach to male and female infertility can significantly benefit the fertility journey for an increasingly large population worldwide. As the founding investor, we are proud to continue supporting the company to deliver their vision, to redefine the future of fertility treatments, and welcome this highly dedicated investor group, who shares that vision.
ReproNovo is pioneering solutions for some of the most overlooked challenges in reproductive medicine and women’s health. We have confidence in their science and are proud to support their commitment to innovation and their mission of bringing novel options to patients. We look forward to seeing their breakthroughs transform women’s health and infertility worldwide.
ReproNovo’s bold vision and commitment to developing treatments for infertility and other areas of women’s health set them apart in reproductive medicine. With less-than-ideal and in some cases non-existent treatments for these indications, ReproNovo’s innovative pipeline and strong experience offer the potential to transform care for countless patients. We are proud to support the company and believe in their ability to drive meaningful change in this field.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
